[HTML][HTML] A review of broadly protective monoclonal antibodies to treat Ebola virus disease
P Rijal, FR Donnellan - Current Opinion in Virology, 2023 - Elsevier
Highlights•mAbs mixture targeting independent epitopes are better therapeutics.•Optimizing
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …
A review of broadly protective monoclonal antibodies to treat Ebola virus disease
P Rijal, FR Donnellan - Current opinion in virology - pubmed.ncbi.nlm.nih.gov
The filovirus vaccine and the therapeutic monoclonal antibody (mAb) research have made
substantial progress. However, existing vaccines and mAbs approved for use in humans are …
substantial progress. However, existing vaccines and mAbs approved for use in humans are …
A review of broadly protective monoclonal antibodies to treat Ebola virus disease.
P Rijal, FR Donnellan - Current Opinion in Virology, 2023 - europepmc.org
The filovirus vaccine and the therapeutic monoclonal antibody (mAb) research have made
substantial progress. However, existing vaccines and mAbs approved for use in humans are …
substantial progress. However, existing vaccines and mAbs approved for use in humans are …